

20 Nov 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech's rollercoaster ride set to continue; new Wegovy data; Novo's plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 November 2023, including: [AstraZeneca PLC](#) CEO on obesity and more; biotech's rollercoaster ride set to continue; new Wegovy data; [Novo Nordisk A/S](#)'s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[AstraZeneca CEO Soriot On Obesity, Gene Therapy And More](#)" - Scrip, 13 Nov, 2023.)

(Also see "[Jefferies Conference Highlights How Biotech's Rollercoaster Ride Will Continue Into 2024](#)" - Scrip, 14 Nov, 2023.)

(Also see "[AHA 2023 – Wegovy Cuts Death Risk, But Will That Be Enough For Payers?](#)" - Scrip, 11 Nov, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Novo Nordisk Has Plans For Semaglutide In NASH Too](#)" - Scrip, 15 Nov, 2023.)

(Also see "[Lilly's Zepbound: The Biggest-Selling Drug In The World, Ever?](#)" - Scrip, 15 Nov, 2023.)

[Click here to explore this interactive content online](#) ✨